TORONTO (BUSINESS WIRE) $ATBPF Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is extending the Early Warrant Exercise Incentive Program (“Early Warrant Exercise Program”) for.
- Study delivers data required for Phase II trial, on track to initiate next quarter- Confirms linear, dose-proportional pharmacokinetics- Complements strong safety data already reportedTORONTO (BUSINESS WIRE) $ATBPF Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leverag.
TORONTO (BUSINESS WIRE) $ATBPF Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held ear.